Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007690 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
A Phase 3 study of Uveal Melanoma and Ocular Melanoma, sponsored by Aura Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06007690 is a Phase 3 study of Uveal Melanoma and Ocular Melanoma that is actively recruiting participants, run by Aura Biosciences. The registered enrollment target is 100 participants, below the 142-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06007690, a Phase 3 study of Uveal Melanoma and Ocular Melanoma, is actively recruiting participants, sponsored by Aura Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Conditions Studied
Interventions
- DRUG Bel-sar
- DEVICE Suprachoroidal Microinjector
- DEVICE Infrared Laser
- DEVICE Sham Infrared Laser
- DEVICE Sham Microinjector
Study Locations (20)
California
- UCSD Shiley Eye Institute, Jacobs Retina Center - La Jolla
- Doris Stein Eye Research Center - Los Angeles
- Stanford University School of Medicine - Palo Alto
- Retinal Consultants Medical Group, Inc. - Sacramento
Florida
- Bascom Palmer Eye Institute - Miami
- Retina Associates of Florida, PA - Tampa
Massachusetts
- Tufts Medical Center New England Eye Center - Boston
- Massachusetts Eye and Ear - Boston
Michigan
- W.K. Kellogg Eye Center - University of Michigan - Ann Arbor
- Associated Retinal Consultants (ARC) P.C. - Royal Oak
Alabama
- Retina Consultants of Alabama - Birmingham
Georgia
- Emory Eye Center - Atlanta
Illinois
- University of Illinois at Chicago - Chicago
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2028-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06007690
The ClinicalTrials.gov registry entry for NCT06007690 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (30% lower). The listed sponsor is Aura Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Uveal Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Bel-sar is the first listed.
NCT06007690 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06007690 about?
NCT06007690 is a clinical study titled "A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma". The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
What is the current status of trial NCT06007690?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-12-06. Estimated completion is 2028-08-15.
What conditions does trial NCT06007690 study?
This clinical trial studies the following conditions: Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma, Indeterminate Lesions.
What interventions are being tested in trial NCT06007690?
The interventions under investigation include: Bel-sar (DRUG), Suprachoroidal Microinjector (DEVICE), Infrared Laser (DEVICE), Sham Infrared Laser (DEVICE), Sham Microinjector (DEVICE).
Who is sponsoring clinical trial NCT06007690?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007690 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RECRUITING · Phase 3
-
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
COMPLETED · Phase 3
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.